| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/01/2004 | CA2499149A1 Mannitol formulation for integrin receptor antagonist |
| 04/01/2004 | CA2499093A1 Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer. |
| 04/01/2004 | CA2499066A1 Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells |
| 04/01/2004 | CA2498943A1 Manufacturing process for no-donating compounds such as no-donating diclofenac |
| 04/01/2004 | CA2498894A1 Combinations of atorvastatin and .alpha.1, adrenergic receptor antagonists |
| 04/01/2004 | CA2498890A1 Modified release formulations of oxcarbazepine and derivatives thereof |
| 04/01/2004 | CA2498781A1 Indolinones substituted by heterocycles, their preparation thereof and their use as medicaments |
| 04/01/2004 | CA2498662A1 Phenol derivatives and their use as rotamase inhibitors |
| 04/01/2004 | CA2498335A1 4-pyrrolidino-phenyl-benzyl ether derivatives |
| 04/01/2004 | CA2498331A1 Formulation for lipophilic agents |
| 04/01/2004 | CA2498325A1 Prophylactic and therapeutic hiv aptamers |
| 04/01/2004 | CA2498149A1 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors |
| 04/01/2004 | CA2497978A1 Compositions and methods for separating amines and amino acids from their counter-enantiomers |
| 04/01/2004 | CA2497977A1 Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| 04/01/2004 | CA2497971A1 Triazole derivatives as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | CA2496332A1 Oral formulations |
| 04/01/2004 | CA2496292A1 Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes |
| 04/01/2004 | CA2495311A1 Use of a quinazoline derivative for treating lower urinary tract symptoms |
| 04/01/2004 | CA2492319A1 Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments |
| 04/01/2004 | CA2486280A1 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 03/31/2004 | EP1403372A2 Composition and methods for the treatment and diagnosis of cardiovascular disease |
| 03/31/2004 | EP1403302A1 Process for producing lactic acid oligomer |
| 03/31/2004 | EP1403269A1 Remedial agent for viral infectious disease |
| 03/31/2004 | EP1403266A1 Process for the industrial synthesis of strontium ranelate and hydrates thereof |
| 03/31/2004 | EP1403250A1 Bis(5-aryl-2-pyridyl) derivative |
| 03/31/2004 | EP1403249A1 Cyclic diamine compounds bearing six-membered cyclic groups |
| 03/31/2004 | EP1403247A1 N-Alkanoylphenylalanine derivatives |
| 03/31/2004 | EP1403243A1 Compounds used to treat alcoholism |
| 03/31/2004 | EP1403235A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same |
| 03/31/2004 | EP1402924A1 Process and composition for the treatment of cardiovascular diseases |
| 03/31/2004 | EP1402900A1 Medicinal compositions |
| 03/31/2004 | EP1402899A1 Remedies for sepsis |
| 03/31/2004 | EP1402895A1 Benzimidazole inhibitors of fructose 1,6-biphosphatase |
| 03/31/2004 | EP1402894A1 Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives |
| 03/31/2004 | EP1402893A1 Pharmaceutical compositions for treatment of secondary hyperparathyroidism and therapeutic agents for cardiovascular complications resulting from the treatment for secondary hyperparathyroidism. |
| 03/31/2004 | EP1402892A1 Antiinflammatoric and antitussive compositions |
| 03/31/2004 | EP1402890A1 Sulfonamide derivatives |
| 03/31/2004 | EP1402889A1 Remedies for diseases caused by nonsense mutation |
| 03/31/2004 | EP1402888A1 The use of substituted carbocyclic compounds as rotamases inhibitors |
| 03/31/2004 | EP1402887A1 New compounds for the inhibition of undesired cell proliferation and use thereof |
| 03/31/2004 | EP1402886A1 Lipolysis accelerator, cosmetic skin preparation for body weight reduction and food or beverage composition each containing the same, and method for reducing body weight and medicinal use each based on activity of the same |
| 03/31/2004 | EP1402884A1 Liposome-containing remedy for the treatment of vascular diseases |
| 03/31/2004 | EP1402882A1 Acid-containing tooth desensitising material |
| 03/31/2004 | EP1402788A1 Body temperature-raising agent of amino acids for eating or drinking and for medical use |
| 03/31/2004 | EP1402786A1 Ximenynic acid |
| 03/31/2004 | EP1402256A2 P-cadherin as a target for anti-cancer therapy |
| 03/31/2004 | EP1402253A2 A process for the isolation of a major harmful oxidant from cigarette smoke |
| 03/31/2004 | EP1402070A2 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 03/31/2004 | EP1402067A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 03/31/2004 | EP1402058A2 Dgks as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1402054A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 03/31/2004 | EP1402053A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402034A2 Identification of ses-1 and the uses of the same |
| 03/31/2004 | EP1402031A2 Atopy |
| 03/31/2004 | EP1402021A1 A gene and uses therefor |
| 03/31/2004 | EP1402019A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
| 03/31/2004 | EP1402018A1 Unigene unidirectional antisense library |
| 03/31/2004 | EP1402017A1 Random gene unidirectional antisense library |
| 03/31/2004 | EP1402007A1 Bcl-2 dnazymes |
| 03/31/2004 | EP1401875A1 Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells |
| 03/31/2004 | EP1401861A2 Cads as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401856A2 Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds |
| 03/31/2004 | EP1401853A1 Modulators of pharmacological agents |
| 03/31/2004 | EP1401841A1 Substituted 1-oxa-2,8-diaza-spiro 4,5]dec-2-ene derivatives as medicaments for the treatment of pain |
| 03/31/2004 | EP1401840A1 Novel 4-amino-5,6-substituted thiopheno 2,3-d]pyrimidines |
| 03/31/2004 | EP1401839A1 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta a]naphthalene |
| 03/31/2004 | EP1401838A2 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
| 03/31/2004 | EP1401837A1 Purine derivatives as a2b adenosine receptor antagonists |
| 03/31/2004 | EP1401836A1 Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
| 03/31/2004 | EP1401835A1 Carboline derivatives as pde-5 inhibitors |
| 03/31/2004 | EP1401834A1 New derivatives of oxazolidinones as antibacterial agents |
| 03/31/2004 | EP1401833A2 Chemical derivatives and the use thereof as an anti-elomerase agent |
| 03/31/2004 | EP1401831A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 03/31/2004 | EP1401830A2 Quinazolinediones as antibacterial agents |
| 03/31/2004 | EP1401829A1 Novel heterocyclic antibacterial compounds |
| 03/31/2004 | EP1401828A1 N-formyl hydroxylamine compounds as inhibitors of pdf |
| 03/31/2004 | EP1401826A1 Pyrazole derivatives as hiv reverse transcriptase inhibitors |
| 03/31/2004 | EP1401825A2 Thiophene derivatives as antiviral agents for flavivirus infection |
| 03/31/2004 | EP1401824A2 Aromatic hydroxamic acid derivatives useful as hdac inhibitors |
| 03/31/2004 | EP1401822A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 03/31/2004 | EP1401821A1 Novel phenylalkyl diamine and amide analogs |
| 03/31/2004 | EP1401820A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401819A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401817A1 Isoquinoline compounds having antiinfective activity |
| 03/31/2004 | EP1401816A1 Process for the production of the piperidine derivative fexofenadine |
| 03/31/2004 | EP1401813A1 New indole derivatives with 5-ht6 receptor affinity |
| 03/31/2004 | EP1401812A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| 03/31/2004 | EP1401810A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 03/31/2004 | EP1401809A1 Tryptase inhibitors |
| 03/31/2004 | EP1401806A1 Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents |
| 03/31/2004 | EP1401801A1 Selective androgen receptor modulators and methods of use thereof |
| 03/31/2004 | EP1401791A2 Non-peptidic cyclophilin binding compounds and their use |
| 03/31/2004 | EP1401506A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy |
| 03/31/2004 | EP1401504A1 Uv-screening peptide-flavonoid conjugates |
| 03/31/2004 | EP1401503A1 Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
| 03/31/2004 | EP1401502A1 Pharmaceutical formulation |
| 03/31/2004 | EP1401498A1 Anti-ngf antibodies for the treatment of various disorders |
| 03/31/2004 | EP1401492A1 Ltb4 as vaccine adjuvant |
| 03/31/2004 | EP1401485A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 4-(2- 4-methane sulfonyl oxyphenyl ethoxy)phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and insulin |